Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cytokinetics (NQ: CYTK ) 55.91 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Cytokinetics < Previous 1 2 3 4 5 6 7 Next > 18 Analysts Have This to Say About Cytokinetics May 05, 2023 Via Benzinga Cytokinetics: Q1 Earnings Insights May 04, 2023 Via Benzinga Analyst Ratings for Cytokinetics April 18, 2023 Via Benzinga Analyst Expectations for Cytokinetics's Future March 31, 2023 Via Benzinga Cytokinetics Plans To Discontinue Late-Stage ALS Trial Due To Futility March 31, 2023 Cytokinetics Incorporated (NASDAQ: CYTK) announced that the Data Monitoring Committee (DMC) for COURAGE-ALS recently convened to conduct the second planned interim analysis of this Phase 3 clinical... Via Benzinga Analyst Ratings for Cytokinetics March 06, 2023 Via Benzinga Cytokinetics Posts Aficamten Data In Patients With Thickened Heart Muscle March 06, 2023 Via Benzinga FDA Rejects Cytokinetics' Heart Failure Treatment Candidate March 01, 2023 Via Benzinga Earnings Scheduled For March 1, 2023 March 01, 2023 Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. Via Benzinga Cytokinetics's Earnings: A Preview February 28, 2023 Via Benzinga Analyst Ratings for Cytokinetics February 17, 2023 Via Benzinga Analyst Ratings for Cytokinetics December 20, 2022 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For February 17, 2023 February 17, 2023 Via Benzinga A Patent Cliff Is Coming For Bristol — Can Billions In New Products Fill The Gap? February 17, 2023 The company's biggest moneymakers are soon to lose patent protection. Via Investor's Business Daily February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More January 31, 2023 The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... Via Benzinga Expert Ratings for Cytokinetics December 20, 2022 Via Benzinga Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors December 27, 2022 Biopharma stocks were not immune to the broader market downturn seen for much of 2022. Via Benzinga Tesla To $175? Here Are 10 Other Price Target Changes For Friday December 23, 2022 Oppenheimer cut CarMax, Inc. (NYSE: KMX) price target from $100 to $75. . Oppenheimer analyst Brian Nagel maintained an Outperform rating on the stock. CarMax shares fell 1.3% to $56.47 in pre-market... Via Benzinga What 7 Analyst Ratings Have To Say About Cytokinetics December 20, 2022 Via Benzinga Cytokinetics AdComm Outcome Might Be Blessing In Disguise, This Analyst Said December 14, 2022 Via Benzinga FDA Adcomm Gives Thumbs Down To Cytokinetics' Heart Failure Candidate December 14, 2022 Via Benzinga Where Cytokinetics Stands With Analysts October 11, 2022 Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings within the last quarter: Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2022 December 20, 2022 Via Benzinga REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday December 14, 2022 U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Wednesday. Here are some big stocks recording gains in today’s session. Via Benzinga Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session December 14, 2022 Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. Via Benzinga Why Cytokinetics Is Soaring After A 'Bruising' FDA Meeting For Its Heart Drug December 14, 2022 The FDA's experts voted 3-8 against the Cytokinetics heart-failure drug. Via Investor's Business Daily Top Stories Today: Jack Dorsey Not Exactly Impressed With Elon Musk's Twitter; Binance Sees $3B Outflow In 7 Days.. December 14, 2022 Benzinga Via Benzinga Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors December 02, 2022 Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%. Via Benzinga Cytokinetics CEO: Why It's OK Not Being An Overnight Success October 25, 2022 The company hopes to come out next year with at least one heart-failure drug. Via Investor's Business Daily Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022 October 11, 2022 Upgrades Via Benzinga < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.